Search

Orion Oyj (Class B)

Closed

68.2

Overview

Share price change

24h

Current

Min

67.6

Max

68.65

Key metrics

By Trading Economics

Income

119M

180M

Sales

62M

417M

P/E

Sector Avg

25.093

37.461

EPS

0.59

Dividend yield

2.44

Profit margin

43.289

Employees

3,700

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.44%

2.33%

Market Stats

By TradingEconomics

Market Cap

619M

9.5B

Previous open

68.2

Previous close

68.2

Orion Oyj (Class B) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 paź 2025, 23:52 UTC

Market Talk

Global Equities Roundup: Market Talk

26 paź 2025, 23:52 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

26 paź 2025, 23:46 UTC

Market Talk

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

26 paź 2025, 23:41 UTC

Market Talk

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

26 paź 2025, 23:34 UTC

Earnings

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

26 paź 2025, 23:32 UTC

Earnings

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

26 paź 2025, 23:30 UTC

Earnings

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

26 paź 2025, 22:29 UTC

Earnings

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

26 paź 2025, 22:29 UTC

Earnings

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

26 paź 2025, 22:29 UTC

Earnings

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

26 paź 2025, 22:29 UTC

Earnings

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

26 paź 2025, 22:16 UTC

Earnings

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

26 paź 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

26 paź 2025, 19:29 UTC

Acquisitions, Mergers, Takeovers

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

26 paź 2025, 06:39 UTC

Earnings

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

26 paź 2025, 06:39 UTC

Earnings

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

26 paź 2025, 06:39 UTC

Earnings

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

24 paź 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 paź 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 paź 2025, 21:07 UTC

Earnings

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 paź 2025, 20:58 UTC

Earnings

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 paź 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 paź 2025, 20:40 UTC

Earnings

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 paź 2025, 20:24 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 paź 2025, 20:23 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 paź 2025, 20:13 UTC

Earnings

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 paź 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 paź 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 paź 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 paź 2025, 19:33 UTC

Earnings

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Orion Oyj (Class B) Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
help-icon Live chat